Expert Ratings for Galera Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Galera Therapeutics (NASDAQ:GRTX) in the last quarter, with 1 bullish and 3 indifferent ratings. The company's average price target has decreased by 57.38% from the previous average price target of $4.13 to $1.76. The high and low price targets are $6.00 and $0.25 respectively.
August 29, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Galera Therapeutics has received mixed ratings from analysts, with a decrease in the average price target, which could impact investor sentiment.
Analyst ratings can significantly influence investor sentiment and stock prices. The mixed ratings and decrease in average price target for Galera Therapeutics indicate a potential negative impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100